GlassScriptPhysician profile
Mei-Chen Wang
NPI 1689277709
$4,309.48
in general payments reported to CMS, 2019-2025
26 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what 85% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $693 · 2022: $781 · 2023: $993 · 2024: $833 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,779 · Education: $56.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,778.80 |
| Education | $56.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,274.45 | 2023-2025 | Repatha, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $688.60 | 2022-2025 | |
| Abbvie INC. | $332.35 | 2021-2025 | |
| Lilly USA, LLC | $256.20 | 2021-2023 | Jardiance, Emgality, Mounjaro |
| Amarin Pharma, INC. | $221.36 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $200.64 | 2021-2024 | Farxiga, Lokelma, Breztri |
| Merck Sharp & Dohme LLC | $186.11 | 2021-2025 | Capvaxive, Gardasil 9, Dificid |
| Esperion Therapeutics, INC. | $185.43 | 2021 | |
| Opko Pharmaceuticals, LLC | $176.98 | 2021-2025 | Rayaldee |
| Gilead Sciences, INC. | $153.27 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $94.89 | 2021-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $66.04 | 2022 | |
| Axsome Therapeutics, INC. | $59.70 | 2024 | Auvelity |
| Travere Therapeutics, INC. | $55.46 | 2024 | |
| Glaxosmithkline, LLC. | $55.31 | 2022-2024 | Trelegy Ellipta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $54.12 | 2024-2025 | Cologuard Collection Kit |
| Seqirus USA INC | $51.43 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $34.43 | 2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $24.97 | 2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $24.34 | 2023 | Jynarque |
| Vifor Pharma, INC. | $22.97 | 2021 | |
| Calliditas Therapeutics US INC. | $22.72 | 2023 | Tarpeyo |
| Redhill Biopharma INC. | $19.95 | 2023 | Talicia |
| Eisai INC. | $19.12 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.09 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mei-Chen Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.